news
06 April 2021
Da Volterra Receives FDA Fast Track Designation for its Novel Microbiome Protector DAV132
• FDA Fast Track Designation has been granted to DAV132 for the prevention of Clostridioides difficile infection, a life-threatening…
The e-poster highlights the need to develop innovative approaches to protect the intestinal microbiota of cancer patients treated with immune checkpoint inhibitors and receiving antibiotics.
The ESMO Virtual Congress 2020 is the global stage for the exchange and debate of translational cancer science of excellence, first announcements of practice-changing data, and multidisciplinary must-have conversations set to spur transformative therapies against cancer.
Link to poster.